Skip to main content

Global In Vitro Fertilization Market to be Valued at USD 37 Billion by 2030 | Skyquest Technology

In vitro fertilization market is segmented on the basis of product, and end-use. Based on product, the market is grouped into fresh donor, fresh non-donor, frozen donor, and frozen non-donor. In terms of end-user, the market is segmented into fertility clinics, surgical centers, hospitals, and research institutes- Industry forecast 2023-2030

Westford,USA, Jan. 17, 2024 (GLOBE NEWSWIRE) — According to SkyQuest report, the global In vitro fertilization market encompasses assisted reproductive technology (ART), encompassing a range of procedures that facilitate the fertilization of an egg with sperm outside the human body. IVF has emerged as a widely embraced and advanced medical technique designed to address infertility issues, offering hope to couples seeking to conceive when natural conception proves challenging.

Browse in-depth TOC on the “In Vitro Fertilization Market”      

  • Pages – 157
  • Tables –  65
  • Figures – 75

There has been a notable shift in societal attitudes towards in-vitro fertilization (IVF), with growing awareness about infertility issues playing a pivotal role in reshaping public perception. The availability of advanced IVF treatments has contributed significantly to the increased acceptance and demand for these procedures in the In vitro fertilization market.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/in-vitro-fertilization-market

Report Scope & Segmentation:                                        

AttributesDetails
Market Size in 2022USD 23.75 Billion
2030 Value ProjectionUSD 37 Billion
CAGR5.7%
Forecast Period2023-2030
Segments Covered
  • Product Type
  • End-use
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Prominent Players inGlobal In Vitro Fertilization Market

  • CooperSurgical, Inc.
  • Vitrolife AB
  • Cook Medical
  • Irvine Scientific
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Esco Micro Pte Ltd
  • Genea Limited
  • Ferring Pharmaceuticals
  • Hamilton Thorne, Inc.
  • Nidacon International AB
  • Rocket Medical plc
  • EMD Serono
  • OvaScience
  • Kitazato Corporation
  • IVFtech Aps
  • Zeiss Group
  • Igenomix
  • Labotect GmbH
  • Esco Medical

Fresh Non-Donor Segment is Expected to Grow in the Market Due to the Increasing Adoption of Fresh Non-Donor Cycles

Fresh non-donor segment has established itself as the dominant player, claiming a substantial 49% share of the revenue in the In vitro fertilization market. Several factors contribute to the evident supremacy of this segment. Firstly, it boasts a remarkably high success rate, making it an attractive choice for individuals and couples seeking fertility treatment[RS1] .

In the markets inNorth America, a notable decline in fertility rates among both men and women has marked a prominent shift in recent years. Several interconnected factors have contributed to the growth of the In-vitro fertilization market in the region. The increasing prevalence of conditions such as polycystic ovary syndrome (PCOS) has led to a rising number of individuals seeking fertility treatments.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/in-vitro-fertilization-market

Frozen Non-Donor Segment is Expected to Dominate Market Due to Increasingly Appealing Option

Frozen non-donor segment is expected to witness the most rapid growth in the In vitro fertilization market. This surge can be attributed to several key factors that make frozen embryo transfers an increasingly appealing option. Frozen transfers yield higher pregnancy rates, enhancing their efficacy as a fertility treatment choice.

Regional markets in the Asia Pacific are poised to rise at a significant CAGR in the In-vitro fertilization market during the forecast period. This growth trajectory can be attributed to a multifaceted set of factors shaping the landscape of fertility treatment in the region.

A comprehensive analysis of the major players in the In vitro fertilizationmarket has been recently conducted. The report encompasses various aspects of the market and its dynamics. This include collaborations, mergers, innovative business policies, and strategies, providing valuable insights into key trends and breakthroughs in the market. Furthermore, the report scrutinizes the market share of the top segments and presents a detailed geographic analysis. Lastly, the report highlights the major players in the industry and their endeavors to develop innovative solutions to cater to the growing demand.

Key Developments in the In Vitro Fertilization Market

  • In 2022, Vitro Life AB introduced a groundbreaking innovation in the field of in-vitro fertilization (IVF) with the launch of their latest product, the Vitro Life G-Series. This new generation of culture media has been meticulously designed to enhance the crucial process of embryo development, thereby significantly improving the success rates of IVF treatments. The Vitro Life G-Series represents a cutting-edge solution that promises to elevate the effectiveness of IVF procedures, providing hope and improved outcomes for individuals and couples seeking fertility treatments.
  • Cooper Surgical, Inc. recently made a strategic move by announcing its acquisition of Origio, a prominent player in IVF laboratory products and services. This acquisition was a pivotal step in Cooper Surgical’s expansion strategy, aimed at diversifying and bolstering its portfolio of IVF solutions.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/in-vitro-fertilization-market

Key Questions Answered in the In Vitro Fertilization Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • List the top companies in the market and explain how they have achieved their positions of influence.
  • In what ways do regional trends and patterns differ within the global market, and how these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Polymerase Chain Reaction (PCR) Market

Global Induced Pluripotent Stem Cells Production Market

Global Protein Therapeutics Market

Global Chemiluminescence Immunoassay Analyzers Market

Global Biobanking Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter


 [RS1]Secondly???

Since the paragraph talks about multiple factors contributing to the growth of this segment, you have to mention at least 3 factors. If not, you can rephrase the paragraph.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.